Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 8:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 1,082 matching trials from the live ClinicalTrials.gov search.
Conditions
Living-Donor Kidney Transplant
Interventions
Thymoglobulin, Campath-1H, Daclizumab
Drug
Lead sponsor
University of Miami
Other
Eligibility
16 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Miami, Florida
Conditions
Hepatitis C, Cirrhosis
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland • Falls Church, Virginia
Conditions
Kidney Transplantation
Interventions
Belimumab
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 60 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Terminated Early Phase 1 Interventional Accepts healthy volunteers Results available

Pneumococcal Conjugate Vaccine in Aging Renal Transplant

NCT03802994
Conditions
Renal Transplantation, Aging
Interventions
23 valent pneumococcal polysaccharide vaccine, 13 valent conjugated pneumococcal vaccine, Peripheral blood sample
Drug · Biological · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
35 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Charleston, South Carolina
Conditions
End Stage Renal Disease (ESRD)
Interventions
Mycophenolic Acid (Myfortic)
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Cincinnati, Ohio
Conditions
Transplant Rejection
Interventions
BIVV020 (SAR445088), Intravenous immunoglobulin (IVIg), Rituximab or biosimilar, Antithymocyte globulin (ATG), Tacrolimus, Mycophenolate, Corticosteroids
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more
Completed No phase listed Observational

Studies of Kidney Transplant Outcome

NCT01277770
Conditions
Transplant Recipient (Kidney), Steroid-Free Maintenance Immunosuppression, Post-Transplant Infections, Thymoglobulin
Interventions
Steroid-Free Maintenance Immunosuppression, Infection After Kidney Transplantation, Evaluation of the DGF nomogram in Thymoglobulin
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
Not listed
Enrollment
7,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Kidney Transplant, Overweight or Obese Adults, Glucose Control
Interventions
Standard medical care, Monitoring Contacts, Behavioral Sessions, Diet, Physical Activity
Other · Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Kidney Transplantation
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
14 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Kidney Transplant Recipient
Interventions
Janssen Ad26.CoV2.S Vaccine, Reduction in Immunosuppression Medication, Maintenance in Immunosuppression Medication
Biological · Other
Lead sponsor
Mark Stegall
Other
Eligibility
18 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Conditions
Hypophosphatemia, Renal Transplant
Interventions
Cinacalcet, Placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
The Bronx, New York
Conditions
BK Virus Infection
Interventions
MAU868, Placebo
Drug · Other
Lead sponsor
Vera Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 11 more
Conditions
Primary Renal Allograft Candidate, Kidney Transplantation
Interventions
Anti-thymocyte Globulin (Rabbit), belatacept, methylprednisolone, basiliximab, mycophenolate mofetil, tacrolimus
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Birmingham, Alabama • San Francisco, California • Atlanta, Georgia
Conditions
Renal Transplantation
Interventions
Enteric-coated mycophenolate sodium (EC-MPS), Mycophenolate mofetil, Placebo to mycophenolate sodium, Placebo to mycophenolate mofetil
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
53
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 40 more
Completed Not applicable Interventional Accepts healthy volunteers

Explore Transplant @Home Within Kaiser Permanente Southern California

NCT03389932
Conditions
End Stage Renal Disease
Interventions
Patient-Guided
Behavioral
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
977 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Pasadena, California
Conditions
Liver Failure, Renal Failure
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
1
States / cities
Fort Worth, Texas
Conditions
Kidney Failure, Chronic
Interventions
Thymoglobulin, Daclizumab, Plasmapheresis, Mycophenolate mofetil, Tacrolimus, Dexamethasone, Prednisone, Cytogam
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Kidney Transplantation
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
8
States / cities
Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 4 more
Conditions
Kidney Transplantation, Treatment Refusal, Patient Compliance
Interventions
Adherence
Behavioral
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Brooklyn, New York
Conditions
Kidney Cancer
Interventions
cyclosporine, fludarabine phosphate, mycophenolate mofetil, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Portland, Oregon
Completed No phase listed Observational Accepts healthy volunteers

Live Kidney Donor Study - Cross-Sectional and Historical Cohort Study

NCT00951977
Conditions
End Stage Renal Disease, Transplantation
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
7,029 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
3
States / cities
Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota
Conditions
Cytomegalovirus (CMV), Kidney Transplant; Complications, Kidney Diseases
Interventions
Valganciclovir (Pre-emptive CMV Therapy), Valganciclovir CMV Prophylaxis
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
8
States / cities
San Francisco, California • Miami, Florida • Atlanta, Georgia + 5 more
Conditions
Kidney Transplant
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Solid Tumor, Adult Central Nervous System Germ Cell Tumor, Adult Rhabdomyosarcoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Soft Tissue Sarcoma, Ewing Sarcoma, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Ovarian Mixed Germ Cell Tumor, Previously Untreated Childhood Rhabdomyosarcoma, Recurrent Adult Brain Tumor, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Extragonadal Germ Cell Tumor, Recurrent Extragonadal Non-seminomatous Germ Cell Tumor, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Neuroblastoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
busulfan, melphalan, topotecan hydrochloride, laboratory biomarker analysis, filgrastim, autologous hematopoietic stem cell transplantation, pharmacological study, autologous bone marrow transplantation
Drug · Other · Biological + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
6 Months to 40 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2024
U.S. locations
1
States / cities
Duarte, California